Filing Details
Silence Therapeutics plc (NASDAQ:SLN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 10, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:SLN
Silence Therapeutics plc (SLN) Files Quarterly Report for Q0
Silence Therapeutics plc (NASDAQ:SLN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 10, 2026.
At publication ·
What changed
Silence Therapeutics plc (NASDAQ:SLN) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Silence Therapeutics plc filed its quarterly report (Form 10-Q) with the SEC on August 10, 2026.
- The company's stock trades at $15.43 with a market capitalization of $304.2 million.
- The 10-Q filing includes unaudited financial statements and management commentary on business performance, though specific revenue figures were not disclosed in this summary.
Market Context
Silence Therapeutics plc's stock currently trades at $15.43 with a market capitalization of $304.2M.
The 10-Q provides Silence Therapeutics plc's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Silence Therapeutics plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SLN Stock Page
Frequently Asked Questions
Where can I read SLN's SEC filings?
Browse all filings on our SLN SEC filings page.
What types of SEC filings does Silence Therapeutics plc file?
Public companies like Silence Therapeutics plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.